GSK•benzinga•
The European Medicines Agency Has Accepted For Review Its Application To Expand The Use Of GSK's Nucala (Mepolizumab) As An Add-on Maintenance Treatment For Patients With Chronic Obstructive Pulmonary Disease With An Eosinophilic Phenotype
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 24, 2025 by benzinga